Kidney Cancer Drugs Market, By Therapy Class (Targeted Therapy, Immunotherapy, and Chemotherapy), By Pharmacologic Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, and Antimetabolites)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2029

Introduction:

Kidney cancer is most common type of cancer in which cancerous cells grow inside the tissues of kidney which affects functioning of the normal cells. Kidney cancer can be caused due to risk factors such as smoking, obesity; inhalation of herbicides, and organic solvents based chemicals, high blood pressure as well as genetic and hereditary factors.

Increasing prevalence of kidney cancer, owing to increasing obesity among the individuals across the globe is a major factor driving growth of the kidney cancer drugs market. In addition, increasing government funding for the research and development of new drugs is expected to propel growth of the target market in the near future. However, lack of awareness about availability of kidney cancer drugs among the individuals is a key factor restraining growth of the kidney cancer drugs market.

The kidney cancer drugs market has been segmented on the basis of therapy class, pharmacologic class, distribution channel, and region.

The therapy class segment includes targeted therapy, immunotherapy and chemotherapy. On the basis of pharmacological class segment the target market has been segmented as angiogenesis inhibitors, mTOR inhibitors, cytokines, and others. Others pharmacological class is further sub-segmented into immune checkpoint inhibitors, ctla-4 inhibitors, and antimetabolites.

On the basis of distribution channel the kidney cancer drugs market has been segmented as hospital, retail pharmacy, and online pharmacy.

Regional Insights:

On the basis of region the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions. This can be attributed to rapid growth in the ratio of kidney cancer disease, advancements in the novel cancer therapies, and well established health care sector in the countries of the region.

Key players operating in the kidney cancer drugs market includes Pfizer Inc., Novartis International AG, Genentech Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Eisai Co., Ltd. and Exelixis, Inc.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for Kidney Cancer Drugs Strategies
     • Key Questions this Study will Answer

     • By Therapy Class (Targeted Therapy, Immunotherapy, and Chemotherapy)

       By Pharmacologic Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, and Antimetabolites))

       By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

       By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Kidney Cancer Drugs Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis

• • Pfizer Inc.

  • Novartis International AG

  • Genentech Inc.

  • Active Biotech AB

  • Amgen Inc.

  • Bayer AG

  • Cipla Limited

  • Hoffmann-La Roche AG

  • Eisai Co., Ltd

  • Exelixis, Inc

1. The Last Word
   • Future Impact
   • About Us
   • Contact